35 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
’ disease progression was measured using the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS
8-K
EX-99.1
x46pdwrai81
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
aku37t9ki5jwuq5q
14 Jul 23
Departure of Directors or Certain Officers
5:01pm
8-K
EX-10.1
vjdn3ag
10 Jul 23
Departure of Directors or Certain Officers
5:08pm
DEF 14A
agw0s9vd
19 May 23
Definitive proxy
4:31pm
10-K
dgqs3jgr
29 Mar 23
Annual report
4:08pm
10-K
EX-3.1
5aqrkc6p6y9krha
29 Mar 23
Annual report
4:08pm
10-K
EX-3.2
727m2f3aozci t4xn
29 Mar 23
Annual report
4:08pm
424B4
kf5425y1y9u6f50xcb
30 Dec 22
Prospectus supplement with pricing info
4:17pm
S-1/A
EX-10.1
q3bn0va8mtg
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
25dz9g6f8lg3z9
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-3.2
68vgo90
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-10.15
fqtyd71v6rwx4d izvi
5 Dec 22
IPO registration (amended)
8:16am
S-1
EX-10.3
lliugm8
18 Nov 22
IPO registration
5:06pm